Test Price
7,800 AED✅ Home Collection Available
ONCOPRO 350 Gene TMB & MSI Profile Test in UAE | 7800 AED | DHA Licensed
Executive Summary & Core Metrics
Comprehensive Genomic Profiling with 99.9% Diagnostic Sensitivity
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing (Cert: INT/EGQ/2509DA/3139).
- Premium Logistics: Secure Medical Courier Solid Tissue Specimen Retrieval for FFPE blocks under ISO Certified Chain-of-Custody.
- Clinical Guidance: Telephonic Post-Test Clinical Guidance for result interpretation by DHA-licensed consultant.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The ONCOPRO 350 gene panel simultaneously profiles 350 cancer-related genes and calculates Tumor Mutational Burden (TMB) together with Microsatellite Instability (MSI) status using advanced Next-Generation Sequencing (NGS). This comprehensive genomic assay serves as a cornerstone of precision oncology, guiding immunotherapy and targeted therapy selection based on the tumor's molecular signature.
| Feature | ONCOPRO 350 Test | Alternative (IHC-MSI + Limited Panel) |
|---|---|---|
| Precision & Depth | 350 genes NGS + quantitative TMB + MSI | MSI by IHC only; gene panel ≤50 genes, no TMB |
| Methodology | NGS, Calculation Algorithms, Derived Ratios | Immunohistochemistry & PCR-based sequencing |
| Turnaround Time | 45 Working Days | 10–14 days (limited scope) |
| Cost | 7,800 AED | ~3,200 AED (incomplete profiling) |
Physician Insight & Safety Protocols
"As a specialist diagnostic radiologist, I emphasize that the ONCOPRO 350 test's genomic data must be integrated with radiological imaging findings for a complete tumor assessment. High TMB or MSI-H results guide immunotherapy decisions, but only after multi-disciplinary tumor board review. Never base treatment changes on genomic data alone without clinical and radiological correlation."
— Mr. Prabhakar Reddy Kalathoor, Specialist Diagnostic Radiology, DHA Registration ID: 61713011
Medication Advisory
Do not discontinue prescribed medication, including chemotherapy or targeted agents, without consulting your treating doctor. This test provides genomic insights, not an immediate substitute for ongoing clinical management.
Exclusion Criteria & Emergency Red Flags
Sample Rejection Risks
- FFPE block with tumor content less than 10%
- Necrotic or heavily decalcified tissue
- Specimens fixed in non-buffered formalin or inadequate fixation time
- Block received outside cold-chain conditions
Immediate Medical Attention Required
- Sudden worsening of cancer symptoms (severe pain, breathing difficulty)
- Signs of spinal cord compression or brain metastasis (confusion, paralysis)
- Uncontrolled bleeding or febrile neutropenia
- Any acute adverse reaction to current therapy
These red flags warrant immediate hospital evaluation regardless of pending test results.
Patient FAQ & Clinical Guidance
1. How does the ONCOPRO 350 test guide my cancer treatment?
This 350-gene assay measures tumor mutational burden and microsatellite instability, enabling your oncologist to select immunotherapy drugs such as pembrolizumab if results reveal high TMB or MSI-H status. The molecular profile provides a roadmap for targeted therapy selection based on your tumor's unique genomic alterations.
2. Why does the test require 45 working days for results?
Comprehensive NGS sequencing of 350 genes, rigorous bioinformatics analysis, and multi-disciplinary clinical sign-off ensure maximum accuracy. Every step follows ISO-certified protocols with expert manual review by molecular pathologists and geneticists.
3. Can the test be performed on a small biopsy sample?
Yes, provided the FFPE block contains at least 10% tumor nuclei and was fixed in neutral buffered formalin. Our pathologists pre-qualify every specimen before initiating NGS to ensure adequate material for reliable results.
UAE Regulatory & Data Privacy Adherence
This laboratory service operates in full compliance with UAE federal laws governing health data protection and patient privacy. All genomic data is processed and stored in accordance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent protocols adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability. DNA Labs UAE is ISO 9001:2015 certified (Cert: INT/EGQ/2509DA/3139) and holds DHA Facility License No. 1143.
Clinical & Logistical Metadata
| Test Name | ONCOPRO 350 Gene TMB & MSI Profile |
| Price (AED) | 7,800 AED |
| Turnaround Time | 45 Working Days |
| Sample Type / Matrix | FFPE Tissue Block / Biopsy Slides (Archival Specimen) |
| Methodology Used | Next-Generation Sequencing (NGS), Calculation Algorithms, Derived Ratios |
| ICD-10-CM Code | Z85.9 |
| LOINC Code | 91850-2 |
| DHA Facility License & Laboratory Address | DHA License No. 1143 | DNA Labs UAE, Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians